Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

In this phase II trial of postmenopausal women with osteoporosis, narlumosbart demonstrated superiority over placebo in increasing BMD at 12 months following administration at 6-month intervals, with ...

A bispecific monoclonal antibody targeting psl and pcrV for chronic Pseudomonas aeruginosa infection in patients with bronchiectasis: Results from a randomized, double-blind, placebo-controlled ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Federal vaccine advisors on Thursday recommended Merck's new RSV antibody shot for infants younger than eight months old in their first respiratory virus season, if their mother didn't receive a ...

Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety. The study began on January 3, 2024, with primary completion expected in 2025.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous pemphigoid, a rare blistering skin disease primarily affecting elderly patients.

Dupilumab treatment in patients with CRSwNP led to a healthier nasal microbiota by increasing beneficial bacteria like Lawsonella and Corynebacterium. The gut microbiota showed no effect, indicating ...

Antibodies Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) ...

Dupixent, which was invented using Regeneron's proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin ...